



Press Release

Source: CLX Medical, Inc.

CLX Medical, Inc. Announces a Definitive Agreement for the Acquisition of the ThyroTest® Rapid Screening Device

Issued Tuesday September 16, 9:42 am ET

MURRIETA, CA--(MARKET WIRE)--Sep. 16, 2008 -- CLX Medical, Inc. (OTC BB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, today announced that the company has executed a definitive agreement to acquire ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease.

ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctors' offices in the U.S., as well as in any non-waived laboratory.

A Current Report on Form 8-K regarding the definitive agreement is expected to be filed with the Securities and Exchange Commission later today.

The definitive agreement was signed with ThyroTec, LLC, the developer of the ThyroTest® device. ThyroTec develops and markets medical diagnostic devices and products for use and application in the medical services industry.

“We are very pleased to announce the definitive agreement for the acquisition of ThyroTest®, which we believe is significantly superior to competitive products,” stated Vera Leonard, chief executive officer of CLX Medical.

“There will be more information regarding the details of the acquisition released over the next several days, including in the 8-K, which will be filed later today. We believe that the acquisition of ThyroTest® will be a major milestone in the development of CLX Medical as we seek to develop long-term value for the company's shareholders,” Ms. Leonard added.

ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctor's offices in the U.S., as well as in any non-waived laboratory. The simple rapid diagnostic test is a qualitative

measurement that allows physicians to screen adult patients for hypothyroidism in approximately ten minutes with a whole blood sample.

Hypothyroidism develops when the thyroid gland does not produce enough thyroid hormone to properly regulate the body's metabolism. A lack of thyroid hormone affects many body systems. The incidence of hypothyroidism tends to increase with age, with older people, especially women, at highest risk. Common symptoms include weight gain, fatigue, mood swings, weakness, dry and coarse skin and hair, hair loss, depression, decreased libido, trouble swallowing, increased cholesterol, heavy or irregular periods or trouble getting pregnant.

Approximately 120 million thyroid-related lab tests are performed in the United States each year. At an estimated average cost of \$40 per test, the U.S. market is currently valued at nearly \$5 billion. Approximately 45 million of those tests are conducted in order to diagnose thyroid dysfunction. CLX believes that ThyroTest[®] is an appropriate, cost-effective first-step for those 45 million diagnostic TSH tests. This current U.S. market opportunity is amplified by the CLIA waived status, which makes the opportunity to meet American Thyroid Association recommendations for screening every individual at age 35 and every five years thereafter a reality.

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit <http://www.clxinvestments.com/email.php>.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxmedical.com) holds a 51% equity interest in Zonda, Inc. (www.zondaincusa.com), which has developed several rapid point of care tests for medical and non-medical markets, including a rapid test for chlamydia. CLX has also entered into a definitive agreement to acquire ThyroTest[®], a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. CLX Medical is focused on the successful worldwide distribution of these and any additional products it may acquire or license.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact:

Gemini Financial Communications, Inc.

A. Beyer

951-677-8073

investors@clxmedical.com